LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

12.15 0.08

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.15

Max

12.15

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

P/E

Sektora vidējais

48.528

110.024

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+55.61% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.26%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-120M

248M

Iepriekšējā atvēršanas cena

12.07

Iepriekšējā slēgšanas cena

12.15

Ziņu noskaņojums

By Acuity

36%

64%

109 / 351 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. febr. 17:37 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

2026. g. 20. febr. 16:18 UTC

Galvenie tirgus virzītāji

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

2026. g. 20. febr. 23:12 UTC

Iegādes, apvienošanās, pārņemšana

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026. g. 20. febr. 22:12 UTC

Peļņas

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 20. febr. 21:23 UTC

Peļņas

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026. g. 20. febr. 21:20 UTC

Tirgus saruna

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026. g. 20. febr. 21:01 UTC

Iegādes, apvienošanās, pārņemšana

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026. g. 20. febr. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

2026. g. 20. febr. 20:17 UTC

Tirgus saruna

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

2026. g. 20. febr. 20:11 UTC

Tirgus saruna

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

2026. g. 20. febr. 19:59 UTC

Tirgus saruna

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

2026. g. 20. febr. 19:58 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

2026. g. 20. febr. 19:49 UTC

Tirgus saruna

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

2026. g. 20. febr. 19:09 UTC

Tirgus saruna

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

2026. g. 20. febr. 19:00 UTC

Tirgus saruna

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

2026. g. 20. febr. 18:28 UTC

Tirgus saruna

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

2026. g. 20. febr. 18:20 UTC

Tirgus saruna

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

2026. g. 20. febr. 18:05 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 20. febr. 18:04 UTC

Tirgus saruna

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

2026. g. 20. febr. 17:38 UTC

Tirgus saruna

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

2026. g. 20. febr. 17:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. febr. 17:24 UTC

Tirgus saruna

Correction to Treasury Yields Fall Market Talk

2026. g. 20. febr. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 20. febr. 16:53 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 20. febr. 16:53 UTC

Tirgus saruna

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

2026. g. 20. febr. 16:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. febr. 16:45 UTC

Tirgus saruna

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

2026. g. 20. febr. 16:40 UTC

Tirgus saruna

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

55.61% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  55.61%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

109 / 351 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat